SYK and Autoimmunity: Thus, as proposed and shown by Duggan et al40, SYK inhibitors, such as fostamatinib, that conventionally target B-cell–driven autoimmune conditions, were capable of inhibiting both STAT and SYK action in EAC cells that reduced their growth.